May 22, 2024

Intravenous (IV) Ibuprofen Market Primed for Growth Driven by Rising Utilization in Acute Pain Management

V ibuprofen is an analgesic nonsteroidal anti-inflammatory drug used for the treatment of moderate to severe pain in adults. As compared to oral ibuprofen, IV formulation provides faster absorption and onset of action within 15 minutes, delivering relieve for acute pain associated with conditions like postsurgical pain and musculoskeletal injuries.

Global Intravenous (IV) Ibuprofen Market is estimated to be valued at US$ 11.13 Billion in 2024 and is expected to exhibit a CAGR of 7.1% over the forecast period 2024 to 2031.

Key Takeaways

Key players operating in the intravenous (IV) ibuprofen market are Cumberland Pharmaceuticals Inc., Hyloris Pharmaceuticals SA, Grifols, S.A., Recordati Rare Diseases Inc., XGEN PHARMACEUTICALS DJB, Inc., AFT Pharmaceuticals, Laboratorios Valmorca, SGPharma Pvt. Ltd., Wellona Pharma, Delex Pharma, Hikma Pharmaceuticals PLC.

The growing prevalence of orthopedic disorders, musculoskeletal injuries, and postsurgical pain indications are fueling the demand for IV ibuprofen formulations for fast-acting analgesic effects.

Leading pharmaceutical companies are Intravenous (IV) Ibuprofen Market Size undertaking initiatives to expand their global footprint through new product launches, collaborations, and geographic expansion into high growth developing markets.

Market Key Trends
The rising adoption of minimal invasive surgeries resulting in reduced hospital stays is driving the utilization of IV ibuprofen formulations that offer convenience of administration and fast relief from acute postsurgical pain.Pharmaceutical manufacturers are focusing on developing enhanced delivery formulations such as intranasal sprays that deliver faster absorption for the treatment of acute moderate to severe pain.

Porter’s Analysis

Threat of new entrants: Low cost of required technologies and raw materials pose low barriers to entry.

Bargaining power of buyers: Large retail pharmacies have significant bargaining power over pricing and terms of sale.

Bargaining power of suppliers: Major players have control over raw materials supply, giving them bargaining advantage over drug manufacturers.

Threat of new substitutes: Alternate drug categories like Paracetamol offer substitution threat, limiting price flexibility.

Competitive rivalry: Presence of many large generics players increases competition on drug pricing and promotional strategies.

Geographical Regions

North America currently holds the largest share of the intravenous ibuprofen market due to high healthcare spending and rising demand for pain management therapies. The presence of major market players and availability of advanced medical facilities also contribute to its dominance.

Asia Pacific is poised to experience the fastest growth over the forecast period owing to increasing incidences of chronic conditions, growing medical tourism, and improving access to healthcare in developing countries. Rising healthcare expenditures, coupled with expansion efforts by international companies, are boosting the market growth in the region.

Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it